Reduced Use of Maintenance Therapies Among People With Cystic Fibrosis Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Australia

Hans Kristian Råket; Tamara Milder; Melisa Litchfield; Camilla Bjørn Jensen; Joanna Nan Wang; Espen Jimenez-Solem; Janne Petersen; Sallie-Anne Pearson; Adam Jaffe; Michael O Falster

doi:10.1016/j.clinthera.2025.05.016

Reduced Use of Maintenance Therapies Among People With Cystic Fibrosis Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Australia

Hans Kristian Råket, Tamara Milder, Melisa Litchfield, Camilla Bjørn Jensen, Joanna Nan Wang, Espen Jimenez-Solem, Janne Petersen, Sallie-Anne Pearson, Adam Jaffe, Michael O Falster

Abstract

PURPOSE: Elexacaftor/tezacaftor/ivacaftor (ETI) is an efficacious targeted therapy for cystic fibrosis, but its impact on the use of maintenance therapies has not been assessed in Australia.

METHODS: We performed a retrospective cohort study including individuals with at least 1 ETI dispensing. Quarterly prevalence of airway therapies, antibiotics, and gastrointestinal and endocrine medications was evaluated 24 months before and after ETI initiation. Odds ratios for dispensing were estimated using mixed-effects logistic regression.

FINDINGS: Airway therapies and oral/inhaled antibiotic use declined after ETI, whereas gastrointestinal and endocrine therapies remained stable.

IMPLICATIONS: Elexacaftor/tezacaftor/ivacaftor is associated with a reduced treatment burden in cystic fibrosis, supporting broader access.

Originalsprog	Engelsk
Tidsskrift	Clinical Therapeutics
Vol/bind	47
Udgave nummer	9
Sider (fra-til)	813-815
Antal sider	3
ISSN	0149-2918
DOI	https://doi.org/10.1016/j.clinthera.2025.05.016
Status	Udgivet - sep. 2025

Adgang til dokumentet

10.1016/j.clinthera.2025.05.016Licens: CC BY

Andre filer og links

Link to publication in Scopus

Citationsformater

Råket, H. K., Milder, T., Litchfield, M., Jensen, C. B., Wang, J. N., Jimenez-Solem, E., Petersen, J., Pearson, S.-A., Jaffe, A., & Falster, M. O. (2025). Reduced Use of Maintenance Therapies Among People With Cystic Fibrosis Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Australia. Clinical Therapeutics, 47(9), 813-815. https://doi.org/10.1016/j.clinthera.2025.05.016

Råket, HK, Milder, T, Litchfield, M, Jensen, CB , Wang, JN , Jimenez-Solem, E , Petersen, J, Pearson, S-A, Jaffe, A & Falster, MO 2025, 'Reduced Use of Maintenance Therapies Among People With Cystic Fibrosis Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Australia', Clinical Therapeutics, bind 47, nr. 9, s. 813-815. https://doi.org/10.1016/j.clinthera.2025.05.016

@article{91662b4f860b43ea849d91902c42758c,

title = "Reduced Use of Maintenance Therapies Among People With Cystic Fibrosis Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Australia",

abstract = "PURPOSE: Elexacaftor/tezacaftor/ivacaftor (ETI) is an efficacious targeted therapy for cystic fibrosis, but its impact on the use of maintenance therapies has not been assessed in Australia.METHODS: We performed a retrospective cohort study including individuals with at least 1 ETI dispensing. Quarterly prevalence of airway therapies, antibiotics, and gastrointestinal and endocrine medications was evaluated 24 months before and after ETI initiation. Odds ratios for dispensing were estimated using mixed-effects logistic regression.FINDINGS: Airway therapies and oral/inhaled antibiotic use declined after ETI, whereas gastrointestinal and endocrine therapies remained stable.IMPLICATIONS: Elexacaftor/tezacaftor/ivacaftor is associated with a reduced treatment burden in cystic fibrosis, supporting broader access.",

keywords = "Adolescent, Adult, Aminophenols/therapeutic use, Anti-Bacterial Agents/therapeutic use, Australia, Benzodioxoles/therapeutic use, Child, Chloride Channel Agonists/therapeutic use, Cystic Fibrosis/drug therapy, Drug Combinations, Female, Humans, Indoles/therapeutic use, Male, Pyrazoles/therapeutic use, Pyridines/therapeutic use, Pyrrolidines/therapeutic use, Quinolines, Quinolones/therapeutic use, Retrospective Studies, Young Adult",

author = "R{\aa}ket, {Hans Kristian} and Tamara Milder and Melisa Litchfield and Jensen, {Camilla Bj{\o}rn} and Wang, {Joanna Nan} and Espen Jimenez-Solem and Janne Petersen and Sallie-Anne Pearson and Adam Jaffe and Falster, {Michael O}",

year = "2025",

month = sep,

doi = "10.1016/j.clinthera.2025.05.016",

language = "English",

volume = "47",

pages = "813--815",

journal = "Clinical Therapeutics",

issn = "0149-2918",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - Reduced Use of Maintenance Therapies Among People With Cystic Fibrosis Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Australia

AU - Råket, Hans Kristian

AU - Milder, Tamara

AU - Litchfield, Melisa

AU - Jensen, Camilla Bjørn

AU - Wang, Joanna Nan

AU - Jimenez-Solem, Espen

AU - Petersen, Janne

AU - Pearson, Sallie-Anne

AU - Jaffe, Adam

AU - Falster, Michael O

PY - 2025/9

Y1 - 2025/9

N2 - PURPOSE: Elexacaftor/tezacaftor/ivacaftor (ETI) is an efficacious targeted therapy for cystic fibrosis, but its impact on the use of maintenance therapies has not been assessed in Australia.METHODS: We performed a retrospective cohort study including individuals with at least 1 ETI dispensing. Quarterly prevalence of airway therapies, antibiotics, and gastrointestinal and endocrine medications was evaluated 24 months before and after ETI initiation. Odds ratios for dispensing were estimated using mixed-effects logistic regression.FINDINGS: Airway therapies and oral/inhaled antibiotic use declined after ETI, whereas gastrointestinal and endocrine therapies remained stable.IMPLICATIONS: Elexacaftor/tezacaftor/ivacaftor is associated with a reduced treatment burden in cystic fibrosis, supporting broader access.

AB - PURPOSE: Elexacaftor/tezacaftor/ivacaftor (ETI) is an efficacious targeted therapy for cystic fibrosis, but its impact on the use of maintenance therapies has not been assessed in Australia.METHODS: We performed a retrospective cohort study including individuals with at least 1 ETI dispensing. Quarterly prevalence of airway therapies, antibiotics, and gastrointestinal and endocrine medications was evaluated 24 months before and after ETI initiation. Odds ratios for dispensing were estimated using mixed-effects logistic regression.FINDINGS: Airway therapies and oral/inhaled antibiotic use declined after ETI, whereas gastrointestinal and endocrine therapies remained stable.IMPLICATIONS: Elexacaftor/tezacaftor/ivacaftor is associated with a reduced treatment burden in cystic fibrosis, supporting broader access.

KW - Adolescent

KW - Adult

KW - Aminophenols/therapeutic use

KW - Anti-Bacterial Agents/therapeutic use

KW - Australia

KW - Benzodioxoles/therapeutic use

KW - Child

KW - Chloride Channel Agonists/therapeutic use

KW - Cystic Fibrosis/drug therapy

KW - Drug Combinations

KW - Female

KW - Humans

KW - Indoles/therapeutic use

KW - Male

KW - Pyrazoles/therapeutic use

KW - Pyridines/therapeutic use

KW - Pyrrolidines/therapeutic use

KW - Quinolines

KW - Quinolones/therapeutic use

KW - Retrospective Studies

KW - Young Adult

UR - http://www.scopus.com/inward/record.url?scp=105008820851&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2025.05.016

DO - 10.1016/j.clinthera.2025.05.016

M3 - Journal article

C2 - 40545418

SN - 0149-2918

VL - 47

SP - 813

EP - 815

JO - Clinical Therapeutics

JF - Clinical Therapeutics

IS - 9

ER -

Reduced Use of Maintenance Therapies Among People With Cystic Fibrosis Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Australia

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater